Cadila Pharma Launches Bilacad Dex Syrup for Allergy Relief

Cadila Pharmaceuticals has launched Bilacad Dex Syrup, a fixed-dose combination for meeting the mounting burden of respiratory and allergic conditions. The triple action formulation comprises of Bilastine (3.3 mg), Dextromethorphan (10 mg), and Phenylephrine (5 mg) per 5ml, offering broad-range relief against sneezing, cough, nasal congestion, and itching.

Bilastine is a second-generation, non-sedative antihistamine drug to relieve allergic symptoms without inducing somnolence and is therefore ideal for day time use. Dextromethorphan Hydrobromide is a central nervous system antitussive that inhibits chronic dry cough through medullary action without impairing breathing functions. Phenylephrine Hydrochloride is a decongestant with its action through vasoconstriction to alleviate nasal congestion and facilitate unobstructed breathing.

Also Read: Biological E Secures HPV9 Vaccine Manufacturing for India and Global Tenders

It is supported by a randomized, open-label multicenter clinical trial that proved non-inferiority to a top bestseller. In a Cureus study (DOI: 10.7759/cureus.75836), dramatic relief from cough and nasal symptoms without sedation has attested to its efficacy and safety.

Bilacad Dex Syrup can be administered orally in adults and adolescents 12 years and older with the dosage of 10 ml every three hours. Geriatric patients also tolerate it. It must not be administered to children younger than 12 years for longer than 7 consecutive days.

Leader's thought: The Evolution of In-Vitro Diagnostics: Trends and Future Prospects

A perfect solution for professionals, students, and individuals needing non-sedative relief, Bilacad Dex has been developed to enhance quality of life without diminishing productivity. The syrup would be extensively available in urban and semi-urban India to assist Cadila's mission to provide affordable and innovative respiratory solutions.